Oncology, cardiology, rare disease, immunology, neurology, and more. The science changes from one area to the next; our job is to have seen enough of yours to get it right the first time. We do the heavy lifting.
Pick an area and see the kind of indications we have already built the science for. You bring the area and the evidence. We do the heavy lifting.
The endpoint story a tumor board actually debates, built from your own readout.
Where teams here usually start →The slowest part of a project is the ramp: learning the mechanism, the endpoints, the way your specialists think. When we have worked the area before, that ramp is already behind us.
You bring the publication and the therapeutic-area context. We bring the pattern of having built it before, and we do the mapping and the build.
Two specialists open the same approved publication in the same experience. Tap one and watch where their journey starts. Neither reads the other’s field first, and it is all one MLR review.
60+ studies, side by side: why your best science never reaches the physicians it was written for, and what the evidence says actually works instead.
Get the free report →The therapeutic area changes the science. It never changes how the science lands. You bring the area and the evidence. We do the heavy lifting.
Personal in every fieldIn every area on the wall above, the same problem repeats: the specialist, the generalist, and the payer open the same evidence with different questions. Smart Pathways gives each of them their own route through one approved story, and one review covers every journey, whichever field it lives in.
See PubVisual Smart Pathways →
Whatever the field, smart nuggets give the physician an approved next step at the moment of interest: ask, request the paper, book time. The specialty changes; the move does not.
See PubVisual Engage →
Every field has the experts its physicians actually listen to. PubVisual KOL builds their recorded commentary into the story, one tap from the data, in your area’s own language.
See PubVisual KOL →Breadth never means a lower bar. Whatever the area, every frame maps to your approved source, so the work is built for MLR from the first frame, in every field we touch.
“They knew our endpoints before we finished explaining them.”
Name the area and send the science. We will show you what we have built in fields like yours and what your evidence would become. On the house. No promises.
Rare and specialist areas are where the heavy lifting matters most. We start from your approved science, and the harder the field, the more the accuracy and the speed of not starting cold are worth.
We work across therapeutic areas, so the terms, the endpoints, and the way your specialists think are usually familiar. Where they are not, we learn them from your source before anything is built.
Yes, and it gets faster as we go. Once we know your area, the second and third indications build on what we already understand, without starting the science over.
We will not tie it to a fixed date. You approve the core the normal way, at script, storyboard, and final animation. From there, that same approved core carries every version, so new cuts and languages do not restart the scientific review. The overall pace tracks your own review, which we plan around with you from day one.
Always. In every area, every frame traces to an approved claim, so the work is structured for MLR from the first frame and fits your existing Veeva workflow.
